Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018
SUMMARY
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 26 molecules. The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2018, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 11 and 3 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Solid Tumor, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Lymphoma, Cervical Cancer, Colon Carcinoma, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Autoimmune Disorders, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Endometrial Cancer, Gliosarcoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 26 molecules. The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2018, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 11 and 3 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Solid Tumor, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Lymphoma, Cervical Cancer, Colon Carcinoma, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Autoimmune Disorders, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Endometrial Cancer, Gliosarcoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
Avacta Life Sciences Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
Fountain Biopharma Inc
GigaGen Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Stcube Inc
Symphogen A/S
TESARO Inc
Xencor Inc
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
(nivolumab + relatlimab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-754111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PDL1 and LAG3 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemiplimab + REGN-3767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-2385 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAG-525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGD-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit LAG3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relatlimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STT-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-033 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-075 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-22841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: TESARO announces data presentation on solid tumors drug candidate TSR-033 at the SITC 2018 Annual Meeting
Sep 17, 2018: Agenus receives milestone payment from Incyte
Sep 03, 2018: Immutep: Progress Towards Clinical Development of IMP761 - a LAG-3 Agonist Antibody
Jul 24, 2018: F-star announces the Achievement of a Clinical Milestone in its Immuno-Oncology Collaboration with Merck
Jul 10, 2018: Symphogen opens investigational new drug application for antibody candidate Sym022
May 21, 2018: F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Apr 03, 2018: Immutep Provides Update On IMP761
Mar 06, 2018: Immutep Announces United States Patent Grant for IMP701 Antibody
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017
Sep 05, 2017: MacroGenics Provides Update on its DART candidate MGD013
Jul 16, 2017: Prima BioMed Announces Second Milestone Payment for IMP701 Program
Jun 04, 2017: Merck Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody
Jun 03, 2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy
May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
Avacta Life Sciences Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
Fountain Biopharma Inc
GigaGen Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Stcube Inc
Symphogen A/S
TESARO Inc
Xencor Inc
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
(nivolumab + relatlimab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-754111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PDL1 and LAG3 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemiplimab + REGN-3767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-2385 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAG-525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGD-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit LAG3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relatlimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STT-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-033 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-075 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-22841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: TESARO announces data presentation on solid tumors drug candidate TSR-033 at the SITC 2018 Annual Meeting
Sep 17, 2018: Agenus receives milestone payment from Incyte
Sep 03, 2018: Immutep: Progress Towards Clinical Development of IMP761 - a LAG-3 Agonist Antibody
Jul 24, 2018: F-star announces the Achievement of a Clinical Milestone in its Immuno-Oncology Collaboration with Merck
Jul 10, 2018: Symphogen opens investigational new drug application for antibody candidate Sym022
May 21, 2018: F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Apr 03, 2018: Immutep Provides Update On IMP761
Mar 06, 2018: Immutep Announces United States Patent Grant for IMP701 Antibody
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017
Sep 05, 2017: MacroGenics Provides Update on its DART candidate MGD013
Jul 16, 2017: Prima BioMed Announces Second Milestone Payment for IMP701 Program
Jun 04, 2017: Merck Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody
Jun 03, 2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy
May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Avacta Life Sciences Ltd, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Crescendo Biologics Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by F-star Biotechnology Ltd, H2 2018
Pipeline by Fountain Biopharma Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Immutep Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by MacroGenics Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Stcube Inc, H2 2018
Pipeline by Symphogen A/S, H2 2018
Pipeline by TESARO Inc, H2 2018
Pipeline by Xencor Inc, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Avacta Life Sciences Ltd, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Crescendo Biologics Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by F-star Biotechnology Ltd, H2 2018
Pipeline by Fountain Biopharma Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Immutep Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by MacroGenics Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Stcube Inc, H2 2018
Pipeline by Symphogen A/S, H2 2018
Pipeline by TESARO Inc, H2 2018
Pipeline by Xencor Inc, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Avacta Life Sciences Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
Fountain Biopharma Inc
GigaGen Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Stcube Inc
Symphogen A/S
TESARO Inc
Xencor Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Avacta Life Sciences Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Crescendo Biologics Ltd
Eli Lilly and Co
F-star Biotechnology Ltd
Fountain Biopharma Inc
GigaGen Inc
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
MacroGenics Inc
Merck & Co Inc
Novartis AG
Regeneron Pharmaceuticals Inc
Stcube Inc
Symphogen A/S
TESARO Inc
Xencor Inc
